Denali Therapeutics
DNLI
19.16
-0.12
-0.62%
Denali Therapeutics
US · DNLI
#2454 by market cap
Listed 2017
19.16
-0.12
-0.62%
Live - 5344 symbols - heartbeat 147s ago
· 2026-10-08 07:00
Pre-market
19.06
-0.52%
After-hours
19.16
0.00%
Overnight
19.16
0.00%
- Market cap
- 3.06B
- P/E (TTM)i
- -6.75
- P/Bi
- 3.67
- EPSi
- -2.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on DNLI?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
35.09 +83.1%
Price target rangecurrent 19.16
Low26.00
Avg35.09
High42.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-25 | B. Riley Securities | -- | BUY | 35.00 |
| 2026-08-11 | J.P. Morgan | -- | BUY | 29.00 |
| 2026-08-07 | William Blair | -- | BUY | -- |
| 2026-08-07 | UBS | -- | BUY | 34.00 |
| 2026-08-07 | BofA Securities | -- | BUY | 31.00 |
| 2026-08-07 | Baird | -- | BUY | 34.00 |
| 2026-08-07 | Morgan Stanley | -- | BUY | 40.00 |
| 2026-08-07 | Stifel | -- | BUY | 41.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 42.00 |
| 2026-08-06 | TD Cowen | -- | BUY | -- |
| 2026-08-06 | BTIG | -- | BUY | 39.00 |
| 2026-07-23 | Morgan Stanley | -- | BUY | 36.00 |
| 2026-07-16 | Deutsche Bank | -- | BUY | 35.00 |
| 2026-07-15 | BofA Securities | -- | BUY | 31.00 |
| 2026-07-13 | Wedbush | -- | BUY | 26.00 |
| 2026-07-13 | H.C. Wainwright | -- | BUY | 42.00 |
| 2026-07-13 | J.P. Morgan | -- | BUY | 29.00 |
| 2026-07-08 | H.C. Wainwright | -- | BUY | 42.00 |
| 2026-06-16 | UBS | -- | BUY | 25.00 |
| 2026-05-26 | Morgan Stanley | -- | BUY | 35.00 |
| 2026-05-22 | William Blair | -- | BUY | -- |
| 2026-05-22 | BofA Securities | -- | BUY | -- |
| 2026-05-22 | Morgan Stanley | -- | BUY | 35.00 |
| 2026-05-22 | Deutsche Bank | -- | BUY | 31.00 |
| 2026-05-22 | H.C. Wainwright | -- | BUY | 42.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.